Opin.AI Breaks Down Barriers in Clinical Trial Participation
In a significant leap forward for clinical trial accessibility, Opyl Limited (ASX:OPL), a new generation company at the forefront of the health technology sector, has announced a major milestone in the development of Opin.AI, an innovative tool designed to enhance public understanding of clinical trials and foster increased participation.
MELBOURNE, AUSTRALIA – Tuesday, September 5th 2023
Clinical trials are a crucial component of healthcare, driving advancements in treatment and potential cures for various diseases. However, despite the growing interest of the public to contribute, the complex language and technical jargon typically used in public trial registries often act as formidable barriers. Opin.AI aims to address this by reframing this critical information into more accessible and understandable language.
Utilising AI and language models, Opin.AI integrates data from global clinical trial registries such as ANZCTR and ClinicalTrials.gov, transforming the information into an easy-to-use database. By reframing health research information, Opin.AI helps potential participants understand opportunities to contribute to health research, thus facilitating greater engagement and participation.
“Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life,” said Dr Hugo Stephenson, Head of Opin. “With Opin.AI, we are providing leading biopharma and health organisations access to emerging AI-assisted technologies and professional guidance to improve healthcare design, development, and delivery.”
Dr Megan Robertson is Director of Research at St Vincent’s Hospital in Melbourne, a major Australian clinical trial site, and adds “When people cannot understand the information about clinical trials, they are less likely to participate in them. This can slow down the development of new treatments and have a negative impact on people’s health – especially when we know far more people are interested in health research than are able to participate.”
While it is still early days for Opin.AI, its potential to revolutionise the clinical trial landscape is considerable. As patients are increasingly willing to share their health data and experiences, particularly if it can improve health outcomes and help others, Opin.AI could become a key tool in increasing clinical trial participation and speeding up the progress of health research.
In addition to its function as an information resource, the Opin.AI platform also serves as a framework for digital media advertising projects, connecting health research sponsors and sites with relevant participants. This aligns with Opyl’s broader mission to leverage social media insights for clinical trial recruitment, thereby enhancing the company’s capacity to offer unprecedented insight and data optimisation opportunities to the life sciences sector.
Headquartered in Melbourne, Australia, and listed on the Australian Stock Exchange, Opyl is a front-runner in the application of AI technologies in the health sector. With the introduction of Opin.AI, the company continues to demonstrate its commitment to improving health outcomes through the optimisation of data assets and the advancement of technologies for life.
For more information on Opin.AI and Opyl Limited, please visit www.Opyl.AI.
About Opyl Limited
Opyl is a new generation company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and professional guidance to understand and improve healthcare design, development, and delivery. With a vision to improve health and wellness by optimising data assets and digital activation to advance technologies for life, Opyl is at the forefront of health technology innovation.
Opyl powers Opin, a digital marketing offering that aims to mitigate the significant risk in recruiting volunteers for clinical trials and health research. Opin.AI is an online portal that collects and translates information on currently recruiting research studies into open, accessible language.
The company is headquartered in Melbourne, Australia, and listed on the Australian Stock Exchange (ASX:OPL).
For queries, please reach:
Anthony Murray, Anthony@Opyl.AI;
Opyl Limited; c/o Engine House, 105 Wellington Street, St Kilda, Victoria 3182, Australia